Industry News

Viatris intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.

Pfizer Inc announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.

RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two.

In-Cosmetics Asia 2022 Exhibition & Conference was held in Bangkok, Thailand from 1st to 3rd November 2022. It is regarded as an annual meeting hub for the Asia Pacific cosmetic and personal care industry, bringing together exhibiting ingredient suppliers and visiting manufacturers keen to source ingredients, learn, network and do business. This is where all areas of the cosmetics industry connect to inspire, share insights and spark potential collaborations.

For the first time Sun Pharma secured the top position by doctor prescriptions. It outperforms Mankind Pharma long stand, according to market research firm, SMSRC.

Sun Pharma is the largest Indian pharma company by capital, but Mankind Pharma was leading market rank for number of doctor prescriptions for a long time. Recently as per market research firm, SMSRC, Sun Pharma, which has topped India’s pharma retail market for years, has now become the leader in prescriptions, bolstered by an increase in field force and a sharper focus on core therapies.

Cipla Limited gets unaudited consolidated financial results for quarter ended September 30th, 2022. Differentiated pipeline unlocking and continued One-India momentum drive core revenue growth of 12 pc and expansion in EBITDA margin.

Revenue growth for the quarter was at 6 pc on a reported basis and a strong 12% on a covid adjusted base of last year; One-India Robust traction in core portfolio across therapies and business segments; 15 pc YoY ex-covid growth.

Moderna's motion to dismiss a patent infringement suit focused on COVID-19 vaccine technology was dismissed after the company argued that the case should be against the U.S. government rather than itself.

Lupin Limited has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd Tablets, 4 mg, of Exeltis USA Inc.

Drospirenone is a progestin medication which is used as contraceptive to prevent pregnancy and in menopausal hormone therapy, among other uses.

New study published in Journal Vaccine suggests that the Biological E COVID-19 vaccine, Corbevax, is highly immunogenic and can be safely administered to the pediatric population as young as 5 years old.

After establishing safety and immunogenicity of Biological-Es CORBEVAX vaccine in the adult population (18–80 years) in Phase 1–3 studies, the vaccine is further tested in children and adolescents in this study.